Consolidated exchange info: Bio-Rad Laboratories, Inc. (NYSE: BIO)

On 16 March 2020, Bio-Rad Laboratories, Inc. (NYSE: BIO) spotted trading -18.72% off 52-week high price. On the other end, the stock has been noted 19.19% away from the low price over the last 52-weeks. The stock changed -3.47% to recent value of $335.71. The stock transacted 303873 shares during most recent day however it has an average volume of 201.25K shares. The company has 32.4M of outstanding shares and 21.42M shares were floated in the market.

Bio-Rad Laboratories, Inc. (BIO) recently reported financial results for the fourth quarter and full year ended December 31, 2019.

2019 Full-Year Highlights

Full-year sales were $2,311.7M contrast to $2,289.4M for the full year of 2018. After normalizing for the impact of currency, full-year sales increased 3.3 percent.

Year-to-date net income for 2019 was $1,758.7M, or $58.27 per share on a fully diluted basis, contrast to $365.6M, or $12.10 per share, respectively, during the same period in 2018.

In February, Bio-Rad’s QXDx AutoDG ddPCR System and QXDx BCR-ABL %IS Kit were the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. The system uses Bio-Rad’s Droplet Digital PCR (ddPCR) technology to monitor and quantitate the molecular response of chronic myeloid leukemia patients undergoing tyrosine kinase inhibitor therapy.

During the second quarter, Bio-Rad reported the launch of an innovative test to aid in the diagnosis of Lyme disease with the FDA clearance of its BioPlex 2200 Lyme Total Assay. Also during the second quarter, Bio-Rad’s IH-500 automated random access system for blood typing and screening, received FDA 510(k) clearance.

In April, Bio-Rad named Ilan Daskal as Executive Vice President and Chief Financial Officer and Andrew Last as Executive Vice President and Chief Operating Officer.

In June, Bio-Rad reported the launch of its scATAC-Seq solution, a single-cell assay for transposase-accessible chromatin using sequencing, offering high capture efficiency and sensitivity for profiling of gene regulation of individual human cells.

In August, Bio-Rad purchased Exact Diagnostics, a leading provider of a broad range of molecular diagnostics controls. With this acquisition, Bio-Rad expanded its line of quality control products in the area of transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.

In November, Bio-Rad installed its QX ONE Droplet Digital PCR System at select consumer labs previous to the official product launch. The system automates the company’s Droplet Digital technology into a single integrated instrument designed for drug development and manufacturing quality control as well as other highly critical testing environments.

2020 Financial Outlook

For the full year 2020, the company anticipates currency-neutral revenue growth of about 4.5 to 5.25 percent and improved profitability with an estimated non-GAAP operating margin of 13.8 to 14.3 percent. Management will discuss this outlook in greater detail on the fourth-quarter and full-year 2019 financial results conference call.

“Looking ahead to 2020, we expect another year of progress driven by a combination of healthy markets, new products, and a focus on operating efficiencies,” Mr. Schwartz stated. “We continue to pursue our goal of 20 percent adjusted EBITDA run rate by the end of the year.”

Its earnings per share (EPS) expected to touch remained 456.30% for this year while earning per share for the next 5-years is expected to reach at 17.80%. BIO has a gross margin of 54.60% and an operating margin of 9.70% while its profit margin remained 76.10% for the last 12 months.   According to the most recent quarter its current ratio was 2.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -10.27% from the mean of 20 days, -10.24% from mean of 50 days SMA and performed -2.27% from mean of 200 days price. Company’s performance for the week was -4.45%, -11.50% for month and YTD performance remained -9.27%.

2021's Most Anticipated Growth & Wealth-Building Opportunity

Join Thousands of Early Adopters Just Like You Who Want to Grow Capital and Truly Understand Cryptocurrency Together

Mary Smith

Mary Smith– Health Industry My Name is Mary Smith, and I am 29 years old who is an industrialist other than a writer. I want to catch the attention of my audience and publishers without sounds too dry and dull. I am that sort of person who adores his spare time by writing my thoughts and ideas for my audience or readers. My writing skills are not confined to any specific field, I wrote on many topics, but healthcare sector and Stock Market articles are always my favorite. I love to express myself by creative modes such as drawing, singing, and writing. I love to spend my leisure time with my beloved cat, sleep or by playing my favorite video games.

2021's Most Anticipated Growth & Wealth-Building Opportunity

Join Thousands of Early Adopters Just Like You Who Want to Grow Capital and Truly Understand Cryptocurrency Together

Close Bitnami banner